Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.

CONCLUSIONS: We identified a pharmacovigilance signal that suggests a risk of potentially serious intestinal obstruction associated with incretin-based drugs, as a class and with a greater signal for DPP4-i. Other studies are needed to confirm and better understand the potential risk of intestinal obstruction associated with incretin-based drugs. PMID: 32418731 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32418731?dopt=Abstract

Source: Therapie - May 10, 2020 Category: Psychiatry & Psychology Authors: Gudin B, Ladhari C, Robin P, Laroche ML, Babai S, Hillaire-Buys D, Faillie JL Tags: Therapie Source Type: research